REG - Renalytix PLC - Foreign Private Issuer re-qualification

RenalytixAnnouncement

17/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250117:nRSQ6832Ta&default-theme=true

RNS Number : 6832T  Renalytix PLC  17 January 2025

Renalytix plc

("Renalytix" or the "Company")

 

Confirmation of "Foreign Private Issuer" re-qualification

 

LONDON and NEW YORK, 17 January 2025 - Renalytix plc (LSE: RENX) (OTCQB:
RNLXY), which is commercialising the only FDA-approved and Medicare reimbursed
prognostic test to support early-stage risk assessment for chronic kidney
disease, confirms that it has re-qualified for Foreign Private Issuer ("FPI")
status.

 

Following the decision to move the listing of the Company's American
Depository Shares ("ADSs") from Nasdaq to the OTC Markets Group Inc., the ADSs
began trading on OTCQB Venture Market under the symbol "RNLXY" on 8 October
2024. The Company anticipates that transferring trading to OTCQB and the
re-acquisition of FPI status will provide associated cost savings of up to
£1.9 million p.a.

 

In addition, following re-qualification as an FPI the Company is no longer
required to file periodic reports on a quarterly basis. The Company will
continue to update shareholders with period end trading updates and financial
results for the six month period ending 31 December and fiscal year ending 30
June.

 

 

For further information, please contact:

 

 Renalytix plc                                www.renalytix.com (http://www.renalytix.com)
 James McCullough, CEO                        Via Walbrook PR

 Stifel (Nominated Adviser and Joint Broker)  Tel: 020 7710 7600
 Nicholas Moore / Nick Harland / Ben Good

 Oberon Capital (Joint Broker)                Tel: 020 3179 5300
 Mike Seabrook / Nick Lovering

 Walbrook PR Limited                          Tel: 020 7933 8780 or renalytix@walbrookpr.com
 Paul McManus / Alice Woodings                Mob: 07980 541 893 / 07407 804 654

 CapComm Partners
 Peter DeNardo                                Tel: 415-389-6400 or investors@renalytix.com

 

About Renalytix (www.renalytix.com (http://www.renalytix.com) )

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in
vitro diagnostics company, focused on optimizing clinical management of kidney
disease to drive improved patient outcomes. Renalytix has received FDA
approval and Medicare reimbursement for kidneyintelX.dkd which is now offered
commercially in the United States.

 

Unrecognized and uncontrolled kidney disease remains one of the largest
barriers to controlling cost and suffering in the United States and the United
Kingdom's medical system, affecting over 14 million and 8 million people,
respectively. After five years of development and clinical validation,
kidneyintelX.dkd is the only FDA-approved and Medicare reimbursed prognostic
tool capable of understanding a patient's risk with kidney disease early where
treatment has maximal effect. kidneyintelX.dkd is now being deployed across
large physician group practices and health systems in select regions of the
United States.

 

The over 10,000 patients that have been tested by kidneyintelX.dkd have
produced a substantial body of real-world performance data. In patient
populations where kidneyintelX.dkd has been deployed, a demonstrated and
significant increase in diagnosis, prognosis, and treatment rates have been
recorded. kidneyintelX.dkd now has full reimbursement established by Medicare,
the largest insurance payer in the United States, at $950 per reportable
result. kidneyintelX.dkd is also recommended for use in the international
chronic kidney disease clinical guidelines (KDIGO).

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPKABNBBKBDDD